Riad El-Dada
Directeur/Membre du Conseil chez Merck Sharp & Dohme (Holdings) Pty Ltd.
Profil
Riad El-Dada is currently a Director at Merck Sharp & Dohme (Holdings) Pty Ltd.
He was previously an Independent Director at Mallinckrodt Plc from 2022 to 2023 and a Director at Viralytics Pty Ltd.
Mr. El-Dada completed his undergraduate degree at Cornell University and his graduate degree at Georgetown University.
Postes actifs de Riad El-Dada
Sociétés | Poste | Début |
---|---|---|
Merck Sharp & Dohme (Holdings) Pty Ltd.
Merck Sharp & Dohme (Holdings) Pty Ltd. MiscellaneousMiscellaneous Merck Sharp & Dohme (Holdings) Pty Ltd. operates as an investment holding company. The company is headquartered in Macquarie Park, Australia. | Directeur/Membre du Conseil | - |
Anciens postes connus de Riad El-Dada
Sociétés | Poste | Fin |
---|---|---|
MALLINCKRODT PLC | Directeur/Membre du Conseil | 14/11/2023 |
VIRALYTICS LTD. | Directeur/Membre du Conseil | - |
Formation de Riad El-Dada
Cornell University | Undergraduate Degree |
Georgetown University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
MALLINCKRODT PLC | Health Technology |
Entreprise privées | 2 |
---|---|
Viralytics Pty Ltd.
Viralytics Pty Ltd. BiotechnologyHealth Technology Viralytics Pty Ltd. engages in the development and commercialization of oncolytic immunotherapies that harness the power of certain viruses to infect and kill cancer cells. Its product, CAVATAK, is a genetically unmodified proprietary formulation of the common cold Coxsackievirus Type A21. The company was founded in 1984 and is headquartered in Sydney, Australia. | Health Technology |
Merck Sharp & Dohme (Holdings) Pty Ltd.
Merck Sharp & Dohme (Holdings) Pty Ltd. MiscellaneousMiscellaneous Merck Sharp & Dohme (Holdings) Pty Ltd. operates as an investment holding company. The company is headquartered in Macquarie Park, Australia. | Miscellaneous |